Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States

BACKGROUND: In the United States, sorafenib monotherapy was approved in 2007 for first-line (1L) treatment of patients with unresectable hepatocellular carcinoma (uHCC). As other therapies have been approved in recent years for hepatocellular carcinoma treatment in later lines, it is essential to as...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Daneng, Gruber, Stephen B, Iyer, Shrividya, Gupta, Sanjay, Tejani, Mohamedtaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631438/
https://www.ncbi.nlm.nih.gov/pubmed/37969411
http://dx.doi.org/10.4251/wjgo.v15.i10.1796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631438/
https://www.ncbi.nlm.nih.gov/pubmed/37969411
http://dx.doi.org/10.4251/wjgo.v15.i10.1796

Ejemplares similares